诺和诺德股价跌幅扩大至28%，创2022年2月以来新低。 ...

智通财经7月29日电，Mike Doustdar被任命为诺和诺德总裁兼首席执行官。 ...

Core Viewpoint - Novo Nordisk has appointed Maziar Mike Doustdar as the new president and CEO, effective August 7, 2025, succeeding Lars Fruergaard Jørgensen, who is stepping down on the same date [1][3]. Company Leadership Changes - Mike Doustdar, currently the executive vice president of International Operations, has a proven track record of driving growth, having more than doubled sales in International Operations to approximately DKK 112 billion in 2024 [2][10]. - Helge Lund, Chair of Novo Nordisk, expressed confidence in Doustdar's leadership abilities and vision for the company, emphasizing the need to address market challenges swiftly [3]. - Other executive changes include the merger of Research & Early Development and Development into a consolidated R&D unit, led by Martin Holst Lange, who will become the chief scientific officer [5][6]. Organizational Structure - Emil Kongshøj Larsen will succeed Mike Doustdar as executive vice president of International Operations, overseeing a region that accounts for about 20% of Novo Nordisk's global sales [8]. - The new executive management team will be effective from August 7, 2025, and will include various key members responsible for different operational areas [9]. Company Background - Novo Nordisk is a leading global healthcare company founded in 1923, focusing on chronic diseases, particularly diabetes, and employs approximately 77,400 people across 80 countries [13].

Novo Nordisk lowers its financial forecast in a surprise update, citing lagging sales of its weight-loss drug Wegovy as it fights to regain its leading position in the obesity market https://t.co/LeXFsFYwwh ...

格隆汇7月29日｜诺和诺德(NVO.US)盘前跳水，现跌逾13%；礼来盘前亦跌逾2%。消息面上，诺和诺 德下调2025财年销售预期，下调与美国减肥药Wegovy销售下降有关。销售前景反映了复合GLP-1的持 续使用，市场扩张放缓，竞争加剧。此外，2025年前六个月，诺和诺德的销售额增长18%，营业利润增 长29%。(格隆汇) ...

金十数据7月29日讯，减肥药制造商诺和诺德周二警告称，全年销售额和营业利润增长将低于此前预 期，这是该公司第二次下调2025年的预期。作为减肥药Wegovy的生产商，诺和诺德正在努力说服投资 者，在减肥药热潮中，它仍能与美国竞争对手礼来保持竞争力。过去一年，诺和的股价大幅下跌。该公 司在一份声明中表示："2025年销售前景下调是由于2025年下半年增长预期的下调。"以当地货币计算， 诺和诺德目前预计2025年销售额将增长8%-14%，低于此前13%-21%的预期。该公司还将营业利润增长 预期从之前的16%-24%下调至10%-16%。 减肥药制造商诺和诺德下调2025年销售增长及利润预期 ...

诺和诺德表示，2025年前六个月，诺和诺德的销售额增长了18%，营业利润增长了29%。 ...

Shares were down 15% at 12:11 p.m. London time, shortly after the announcement (7:12 a.m. ET). The company said the lower outlook was driven by weaker second-half U.S. sales growth forecasts for its Wegovy weight loss drug and Ozempic diabetes treatment. "For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than- expected market expansion and competition," it added in a statement. This is a developing story. Please check back for updates. Medical bottles and a syr ...

Core Viewpoint - Novo Nordisk reported significant sales and operating profit growth for the first half of 2025, but has adjusted its full-year outlook downward due to lower growth expectations for key products like Wegovy® and Ozempic® in the US market [2][4]. Financial Performance - In the first six months of 2025, sales increased by 18% and operating profit grew by 29%, both at constant exchange rates (CER) [2]. - For the second quarter of 2025, sales growth was 18% and operating profit growth (EBIT) was 40% [3]. - The diluted earnings per share for the first half of 2025 was DKK 12.49 [3]. Updated Outlook - The full-year sales growth is now expected to be between 8-14%, down from a previous estimate of 13-21% [4]. - Operating profit growth is now projected at 10-16%, reduced from 16-24% [4]. - The lowered outlook is attributed to decreased growth expectations for Wegovy® and Ozempic® in the US, as well as lower-than-expected penetration in select markets [4][5]. Product-Specific Insights - Wegovy® sales in the US are affected by competition and slower market expansion, despite the launch of NovoCare® Pharmacy [5][7]. - Ozempic® faces similar challenges due to increased competition in the US market [9]. - The company is actively pursuing strategies to combat the impact of compounded GLP-1s and protect its market position [6]. Financial Items and Cash Flow - Novo Nordisk expects financial items (net) for 2025 to yield a gain of around DKK 3 billion, primarily from hedged currencies [12]. - Free cash flow is projected to be between DKK 35-45 billion, reflecting lower-than-expected sales growth [13].

Core Insights - Novo Resources Corp. has reported significant advancements in its gold exploration and development portfolio across Australia, with a focus on high-grade gold projects and a strong pipeline of upcoming drilling activities [1][2][5] Exploration and Development Activities - The company has completed its maiden RC drill program at the Clone prospect within the Tibooburra Gold Project, yielding high-grade gold intercepts such as 12 m at 5.90 g/t Au and 17 m at 2.40 g/t Au [5][19][23] - At the John Bull Gold Project, four Key Target Areas for drilling have been identified, with soil anomalies extending over 1.5 km and peak results of 1.59 g/t Au from soil sampling [8][9][10] - Exploration at the Sherlock Crossing Au-Sb prospect has defined a coherent 1.5 km antimony soil anomaly, with peak results of 85 ppb Au and 48.3 ppm Sb [37][38] Financial Position - As of June 30, 2025, the company reported a cash balance of A$7 million (C$6 million) and investments valued at approximately A$34 million (C$30 million) [57][58] Future Plans - Novo has planned a ~1,750 m RC drill program at John Bull in H2 2025, contingent on drill rig availability [24] - Follow-up drilling at the Clone prospect is also planned to test the northern extension of the high-grade shoot defined in recent drilling [25] - Further exploration activities are set for the Balla Balla Gold Project and the Southeast Wyloo Au-Sb-Ag-Cu Project, with RC drilling planned for H2 2025 [28][48]